2026 NPPES data Hematology & Oncology Physician NPI 1578921664 MD PHD
Verify on CMS →

MALIN HULTCRANTZ, MD PHD

Hematology & Oncology Physician in NEW YORK, New York. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
621
Medicare Part D claims · 95 beneficiaries · Hematology & Oncology Physician avg: 847
MIPS score
79.0323/100
▼ 4 pts below national avg 83.1 · [object Object]
Industry payments
$3.5K
6 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

MALIN HULTCRANTZ, MD PHD reported a CMS MIPS final score of 79.0323/100 — below the 83.1 national average — and filed 621 Medicare Part D claims in 2023.

79.0323/100
MIPS score · -4 vs avg
621
Part D claims, 2023
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

MALIN HULTCRANTZ, MD PHD's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

79 30th percentile higher than 30% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). This entry sits in this band. 80–90: 129,887 scored providers (27%). Above this entry. 90–100: 189,403 scored providers (40%). Above this entry. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

MALIN HULTCRANTZ, MD PHD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about MALIN HULTCRANTZ, MD PHD?

Near national average

NPI registry status

Active

Issued 02/03/2016

NPI 1578921664

Primary specialty

Hematology & Oncology Physician

Mid-sized

11,215 US NPIs in this specialty

Medicare Part D claims

621 27% vs specialty avg

2023 prescription claims

Specialty avg: 847

MIPS final score

79.0323/100 4.067699999999988% pts

Above neutral band

vs 83.1 national avg

Specialty distribution in New York

How Hematology & Oncology Physician compares to other specialties among New York providers

New York providers

Hematology & Oncology Physician share within New York

1. Hematology & Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Hematology & Oncology Physician share within New York

Medicare quality performance — MIPS

MALIN HULTCRANTZ, MD PHD's 2023 MIPS final score plotted against the Hematology & Oncology Physician national average

Near national average
MIPS Final Score
79.0323/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Hematology & Oncology Physician) — 79.0323/100 vs national avg 83.1

0%100%National avg83%79%
MIPS final score (Hematology & Oncology Physician) — 79.0323/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MALIN HULTCRANTZ, MD PHD appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding MD PHD credentials at 1275 YORK AVE, NEW YORK, NY, 10065, with a listed phone of (212) 639-5126. NPI 1578921664 was issued on 02/03/2016. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what HULTCRANTZ most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 621 prescription claims written by this provider, covering 95 Medicare beneficiaries and totaling roughly $1.1 million in drug spend, with an opioid prescribing rate of 6.8%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 79.0323/100 for the 2023 performance year (Quality 69.4497), compared with the national average of 83.1.

Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

1275 YORK AVE
NEW YORK, NY 10065

Provider Details

NPI 1578921664
Specialty Hematology & Oncology Physician
Credentials MD PHD
Gender Female
NPI Issued 02/03/2016

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

79.0323
Final Score
Avg: 83.1
69.4497
Quality

Reporting: Group practice

Hospital and facility affiliations

Facilities where MALIN HULTCRANTZ, MD PHD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

MEMORIAL HEMATOLOGY LYMPHOMA GROUP
NEW YORK, NY

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MALIN HULTCRANTZ, MD PHD. Source: openpaymentsdata.cms.gov.

Total received

$3.5K

Largest payer

E.R. Squibb & Sons, L.L.C.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — New York NYSBPMC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 — they are NOT specific to MALIN HULTCRANTZ, MD PHD. To verify MALIN HULTCRANTZ, MD PHD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases

NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

621
Total Claims
$1.1M
Total Drug Cost
95
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
972
Total Day Supply
27,357
Generic Drug Cost
$170K
Opioid Claims
42 (6.8% rate)

Patient Demographics

Average Patient Age
72.8 years
Avg HCC Risk Score
3.29
Gender Split
55% female / 45% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What MALIN HULTCRANTZ, MD PHD prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Acyclovir
194
Omeprazole
68
Xarelto
Rivaroxaban
30
Valacyclovir
Valacyclovir Hcl
29
Revlimid
Lenalidomide
24
Pantoprazole Sodium
22
Dexamethasone
17
Eliquis
Apixaban
16
Tramadol Hcl
16
Pomalyst
Pomalidomide
15

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Hematology & Oncology Physician Overview

How MALIN HULTCRANTZ, MD PHD fits within the Hematology & Oncology Physician landscape nationally.

11,215
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider

MALIN HULTCRANTZ, MD PHD's 621 claims are below the specialty average of 847.

Nearby Hematology & Oncology Physician Providers in New York

Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as HULTCRANTZ.

Compare Hematology & Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is MALIN HULTCRANTZ, MD PHD's specialty?
MALIN HULTCRANTZ, MD PHD specializes in Hematology & Oncology Physician and practices in NEW YORK, New York. Credentials: MD PHD.
How much does MALIN HULTCRANTZ, MD PHD prescribe under Medicare Part D?
In 2023, MALIN HULTCRANTZ, MD PHD wrote 621 Medicare Part D claims totaling $1.1M in drug costs for 95 beneficiaries.
What is MALIN HULTCRANTZ, MD PHD's Medicare quality score?
MALIN HULTCRANTZ, MD PHD has a CMS MIPS Final Score of 79.0323/100 (Quality: 69.4497). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is MALIN HULTCRANTZ, MD PHD located?
MALIN HULTCRANTZ, MD PHD is located at 1275 YORK AVE, NEW YORK, NY, 10065. Phone: (212) 639-5126.
What is MALIN HULTCRANTZ, MD PHD's NPI number?
MALIN HULTCRANTZ, MD PHD's National Provider Identifier (NPI) is 1578921664, issued on 02/03/2016.
Does MALIN HULTCRANTZ, MD PHD prescribe opioids?
Yes, MALIN HULTCRANTZ, MD PHD had 42 opioid claims in 2023 with an opioid prescribing rate of 6.8%.
How many Hematology & Oncology Physician providers are there in the US?
There are 11,215 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does MALIN HULTCRANTZ, MD PHD prescribe most often?
Based on 2023 Medicare Part D data, MALIN HULTCRANTZ, MD PHD's most frequently prescribed drugs include Acyclovir, Omeprazole, Xarelto. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MALIN HULTCRANTZ, MD PHD accept Medicare?
MALIN HULTCRANTZ, MD PHD appears in CMS Medicare data with 621 Part D claims and 95 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MALIN HULTCRANTZ, MD PHD's credentials?
MALIN HULTCRANTZ, MD PHD's NPI is 1578921664 with credentials MD PHD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology